Susannah G Ellsworth

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1699206/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The association of age with acute toxicities in NRG oncology combined modality lower GI cancer trials. Journal of Geriatric Oncology, 2022, 13, 294-301.	1.0	4
2	Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 783-791.e1.	4.9	16
3	Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons. Neuro-Oncology, 2021, 23, 284-294.	1.2	78
4	Outcomes of Neoadjuvant Chemotherapy Versus Chemoradiation in Localized Pancreatic Cancer: A Case–Control Matched Analysis. Annals of Surgical Oncology, 2021, 28, 3779-3788.	1.5	12
5	RE: Valstar et al., "The tubarial salivary glands: A potential new organ at risk for radiotherapyâ€. Radiotherapy and Oncology, 2021, 154, 312-313.	0.6	6
6	Patient-Specific Lymphocyte Loss Kinetics as Biomarker of Spleen Dose in Patients Undergoing Radiation Therapy for Upper Abdominal Malignancies. Advances in Radiation Oncology, 2021, 6, 100545.	1.2	10
7	A Pancreatic Cancer Multidisciplinary Clinic Eliminates Socioeconomic Disparities in Treatment and Improves Survival. Annals of Surgical Oncology, 2021, 28, 2438-2446.	1.5	16
8	ASO Visual Abstract: A Pancreatic Cancer Multidisciplinary Clinic Eliminates Socioeconomic Disparities in Treatment and Improves Survival. Annals of Surgical Oncology, 2021, 28, 2449-2450.	1.5	1
9	Radiation-Induced Lymphopenia Risks of Photon Versus Proton Therapy for Esophageal Cancer Patients. International Journal of Particle Therapy, 2021, 8, 17-27.	1.8	11
10	Circulating Lymphocyte Counts Early During Radiation Therapy Are Associated With Recurrence in Pediatric Medulloblastoma. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1044-1052.	0.8	6
11	Higher Radiation Dose to the Immune Cells Correlates with Worse Tumor Control and Overall Survival in Patients with Stage III NSCLC: A Secondary Analysis of RTOG0617. Cancers, 2021, 13, 6193.	3.7	39
12	Functional liver-image guided hepatic therapy (FLIGHT): A technique to maximize hepatic functional reserve. Medical Dosimetry, 2020, 45, 117-120.	0.9	5
13	A Validation Study on IDO Immune Biomarkers for Survival Prediction in Non–Small Cell Lung Cancer: Radiation Dose Fractionation Effect in Early-Stage Disease. Clinical Cancer Research, 2020, 26, 282-289.	7.0	19
14	A framework for modeling radiation induced lymphopenia in radiotherapy. Radiotherapy and Oncology, 2020, 144, 105-113.	0.6	26
15	Radiosurgery dose reduction for brain metastases on immunotherapy (RADREMI): A prospective phase I study protocol. Reports of Practical Oncology and Radiotherapy, 2020, 25, 500-506.	0.6	6
16	Baseline Karnofsky performance status is independently predictive of death within 30 days of intracranial radiation therapy completion for metastatic disease. Reports of Practical Oncology and Radiotherapy, 2020, 25, 698-700.	0.6	5
17	Exploiting tumor position differences between deep inspiration and expiration in lung stereotactic body radiation therapy planning. Medical Dosimetry, 2020, 45, 293-297.	0.9	2
18	Tumor Size Differences Between Preoperative Endoscopic Ultrasound and Postoperative Pathology for Neoadjuvant-Treated Pancreatic Ductal Adenocarcinoma Predict Patient Outcome. Clinical Gastroenterology and Hepatology, 2020, , .	4.4	5

#	Article	IF	CITATIONS
19	Ultra-high dose rate effect on circulating immune cells: A potential mechanism for FLASH effect?. Radiotherapy and Oncology, 2020, 149, 55-62.	0.6	84
20	Demographic factors associated with missed follow-up among solid tumor patients treated at a large multi-site academic institution. Future Oncology, 2020, 16, 2635-2643.	2.4	4
21	Nearly Half of Metastatic Brain Disease Patients Prescribed 10 Fractions of Whole-Brain Radiation Therapy Die Without Completing Treatment. Journal of Pain and Symptom Management, 2019, 58, e5-e6.	1.2	1
22	Assessing the interactions between radiotherapy and antitumour immunity. Nature Reviews Clinical Oncology, 2019, 16, 729-745.	27.6	183
23	Machine Learning to Build and Validate a Model for Radiation Pneumonitis Prediction in Patients with Non–Small Cell Lung Cancer. Clinical Cancer Research, 2019, 25, 4343-4350.	7.0	16
24	Aquaporin-4 Expression Patterns in Glioblastoma Pre-Chemoradiation and at Time of Suspected Progression. Cancer Investigation, 2019, 37, 67-72.	1.3	4
25	In Regard to Schaub etÂal. International Journal of Radiation Oncology Biology Physics, 2019, 103, 1284-1285.	0.8	1
26	Comprehensive Analysis of the Kinetics of Radiation-Induced Lymphocyte Loss in Patients Treated with External Beam Radiation Therapy. Radiation Research, 2019, 193, 73.	1.5	23
27	Pretreatment PET/CT imaging of angiogenesis based on 18F-RGD tracer uptake may predict antiangiogenic response. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 940-947.	6.4	23
28	Predictors of Nodal and Metastatic Failure in Early Stage Non–small-cell Lung Cancer After Stereotactic Body Radiation Therapy. Clinical Lung Cancer, 2019, 20, 186-193.e3.	2.6	3
29	Development of a Fully Cross-Validated Bayesian Network Approach for Local Control Prediction in Lung Cancer. IEEE Transactions on Radiation and Plasma Medical Sciences, 2019, 3, 232-241.	3.7	42
30	Effects of Proton Center Closure on Pediatric Case Volume and Resident Education at an Academic Cancer Center. International Journal of Radiation Oncology Biology Physics, 2018, 100, 710-718.	0.8	2
31	A model combining age, equivalent uniform dose and IL-8 may predict radiation esophagitis in patients with non-small cell lung cancer. Radiotherapy and Oncology, 2018, 126, 506-510.	0.6	10
32	Serum MicroRNA Signature Predicts Response to High-Dose Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 100, 107-114.	0.8	28
33	What Happens When Proton Meets Randomization: Is There a Future for Proton Therapy?. Journal of Clinical Oncology, 2018, 36, 1777-1779.	1.6	9
34	Field size effects on the risk and severity of treatment-induced lymphopenia in patients undergoing radiation therapy for solid tumors. Advances in Radiation Oncology, 2018, 3, 512-519.	1.2	116
35	Functional liver image guided hepatic therapy (FLIGHT) with hepatobiliary iminodiacetic acid (HIDA) scans. Practical Radiation Oncology, 2018, 8, 429-436.	2.1	8
36	Histology, Tumor Volume, and Radiation Dose Predict Outcomes in NSCLC Patients After Stereotactic Ablative Radiotherapy. Journal of Thoracic Oncology, 2018, 13, 1549-1559.	1.1	31

#	Article	IF	CITATIONS
37	A multiobjective Bayesian networks approach for joint prediction of tumor local control and radiation pneumonitis in nonsmallâ€cell lung cancer (<scp>NSCLC</scp>) for responseâ€adapted radiotherapy. Medical Physics, 2018, 45, 3980-3995.	3.0	43
38	Clinical, Radiographic, and Pathologic Findings in Patients Undergoing Reoperation Following Radiation Therapy and Temozolomide for Newly Diagnosed Glioblastoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 219-222.	1.3	5
39	A Multidisciplinary Approach to Pancreas Cancer in 2016: A Review. American Journal of Gastroenterology, 2017, 112, 537-554.	0.4	123
40	Early Assessment of Treatment Responses During Radiation Therapy for Lung Cancer Using Quantitative Analysis of Daily Computed Tomography. International Journal of Radiation Oncology Biology Physics, 2017, 98, 463-472.	0.8	19
41	Lower Incidence of Esophagitis in the Elderly Undergoing Definitive Radiation Therapy for Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 539-546.	1.1	12
42	Plasma Levels of IL-8 and TGF-β1 Predict Radiation-Induced Lung Toxicity in Non-Small Cell Lung Cancer: A Validation Study. International Journal of Radiation Oncology Biology Physics, 2017, 98, 615-621.	0.8	48
43	Principal component analysis identifies patterns of cytokine expression in non-small cell lung cancer patients undergoing definitive radiation therapy. PLoS ONE, 2017, 12, e0183239.	2.5	11
44	Survival after recurrence following curative intent resection of pancreatic adenocarcinoma Journal of Clinical Oncology, 2017, 35, e15760-e15760.	1.6	0
45	Survival in patients with hepatocellular carcinoma (HCC): A report of 1444 patients treated within a multidisciplinary program Journal of Clinical Oncology, 2017, 35, e15652-e15652.	1.6	1
46	Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization. Contemporary Clinical Trials, 2016, 50, 143-149.	1.8	25
47	Patterns of Radiation-Associated Lymphopenia in Children with Cancer. Cancer Investigation, 2016, 34, 32-38.	1.3	6
48	Comparison of the Effectiveness of Radiofrequency Ablation With Stereotactic Body Radiation Therapy in Inoperable Stage I Non-Small Cell Lung Cancer: A Systemic Review and Pooled Analysis. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1378-1390.	0.8	83
49	Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 94, 571-579.	0.8	172
50	Comment on â€~Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma'. British Journal of Cancer, 2015, 113, 1632-1633.	6.4	4
51	Survival in Patients With Severe Lymphopenia Following Treatment With Radiation and Chemotherapy for Newly Diagnosed Solid Tumors. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1225-1231.	4.9	232
52	The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 259-265.	1.3	171
53	In Reply to Raince and Bloom and Olson. International Journal of Radiation Oncology Biology Physics, 2015, 91, 452-453.	0.8	0
54	Nondosimetric Risk Factors for Radiation-Induced Lung Toxicity. Seminars in Radiation Oncology, 2015, 25, 100-109.	2.2	110

#	Article	IF	CITATIONS
55	Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas. Journal of Gastrointestinal Oncology, 2015, 6, 115-25.	1.4	22
56	Sustained CD4 ⁺ T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide. OncoImmunology, 2014, 3, e27357.	4.6	62
57	Methylprednisolone for the Prophylaxis of Pain Flare: Commentary on Yousef and El-mashad. Journal of Pain and Symptom Management, 2014, 48, 759.	1.2	0
58	High-dose-rate intraoperative radiation therapy: the nuts and bolts of starting a program. Journal of Contemporary Brachytherapy, 2014, 1, 99-105.	0.9	10
59	Patterns of Care Among Patients Receiving Radiation Therapy for Bone Metastases at a Large Academic Institution. International Journal of Radiation Oncology Biology Physics, 2014, 89, 1100-1105.	0.8	45
60	Changes in circulating lymphocyte counts and tumor-infiltrating lymphocyte subpopulations among patients receiving endorectal brachytherapy for rectal adenocarcinoma Journal of Clinical Oncology, 2014, 32, 500-500.	1.6	2
61	Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas Journal of Clinical Oncology, 2014, 32, 269-269.	1.6	15
62	Effects of gemcitabine and stereotactic body radiotherapy on quality of life in locally advanced pancreatic cancer Journal of Clinical Oncology, 2014, 32, 278-278.	1.6	0
63	Pre and postradiation lymphopenia predicts survival in management of bone metastases Journal of Clinical Oncology, 2014, 32, 9563-9563.	1.6	0
64	Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor–vessel relationships. Journal of Radiation Oncology, 2013, 2, 413-425.	0.7	74
65	Radiation Oncologists, Mortality, and Treatment Choices. International Journal of Radiation Oncology Biology Physics, 2013, 87, 437-439.	0.8	5
66	Patterns of palliative radiation near the end of life: A single-institution retrospective analysis Journal of Clinical Oncology, 2013, 31, 9636-9636.	1.6	3
67	First report of the correlation of PET Response Criteria in Solid Tumors (PERCIST) criteria and pathologic change in patients with rectal cancer treated with neoadjuvant radiation Journal of Clinical Oncology, 2013, 31, 261-261.	1.6	1
68	Phase II study of erlotinib combined with adjuvant chemoradiation and chemotherapy for resectable pancreatic cancer Journal of Clinical Oncology, 2013, 31, 269-269.	1.6	1
69	Prognostic factors for achieving resection following neoadjuvant radiation therapy for borderline resectable pancreatic adenocarcinoma Journal of Clinical Oncology, 2013, 31, 285-285.	1.6	0
70	Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas Journal of Clinical Oncology, 2013, 31, e15028-e15028.	1.6	1
71	Is successful resection following neoadjuvant radiation therapy for borderline resectable pancreatic cancer dependent on improved tumor-vessel relationships?. Journal of Clinical Oncology, 2013, 31, 4057-4057.	1.6	1
72	The relevance of transforming growth factor β1 in pulmonary injury after radiation therapy. Lung Cancer, 1998, 19, 109-120.	2.0	58

#	Article	IF	CITATIONS
73	Potential Determinants for Radiation-Induced Lymphopenia in Patients With Breast Cancer Using Interpretable Machine Learning Approach. Frontiers in Immunology, 0, 13, .	4.8	3